MX2016000384A - Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. - Google Patents

Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.

Info

Publication number
MX2016000384A
MX2016000384A MX2016000384A MX2016000384A MX2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A MX 2016000384 A MX2016000384 A MX 2016000384A
Authority
MX
Mexico
Prior art keywords
vegf antagonist
treating
chorioretinal neovascular
child
permeability disorders
Prior art date
Application number
MX2016000384A
Other languages
English (en)
Spanish (es)
Inventor
Sergey Aksenov
Gabriela Burian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016000384A publication Critical patent/MX2016000384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2016000384A 2013-07-11 2014-07-09 Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos. MX2016000384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845064P 2013-07-11 2013-07-11
PCT/IB2014/062978 WO2015004616A1 (en) 2013-07-11 2014-07-09 Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients

Publications (1)

Publication Number Publication Date
MX2016000384A true MX2016000384A (es) 2016-04-29

Family

ID=51211282

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000384A MX2016000384A (es) 2013-07-11 2014-07-09 Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.

Country Status (11)

Country Link
US (2) US20160168240A1 (https=)
EP (1) EP3019526A1 (https=)
JP (1) JP2016528202A (https=)
KR (1) KR20160029794A (https=)
CN (1) CN105377891A (https=)
AU (2) AU2014288837A1 (https=)
BR (1) BR112016000177A2 (https=)
CA (1) CA2917807A1 (https=)
MX (1) MX2016000384A (https=)
RU (1) RU2676274C2 (https=)
WO (1) WO2015004616A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
CN106456757A (zh) * 2014-05-12 2017-02-22 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2894802T3 (es) 2015-09-23 2022-02-15 Aerpio Pharmaceuticals Inc Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular
CN108290004A (zh) * 2015-11-18 2018-07-17 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3454903A4 (en) * 2016-05-13 2020-08-19 Askgene Pharma, Inc. NEW DOUBLE ANTAGONISTS OF ANGIOPOIETIN 2, VEGF
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
US20190388522A1 (en) * 2017-01-25 2019-12-26 Iconic Therapeutics, Inc. Methods for treating disorders associated with angiogenesis and neovascularization
BR112019023061A2 (pt) * 2017-05-01 2020-06-09 Ojai Retinal Tech Llc processo para prevenir ou tratar miopia
SG11202004560TA (en) * 2017-11-16 2020-06-29 Iveric Bio Inc A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv)
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220118419A (ko) * 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물
RU2762991C1 (ru) * 2021-09-06 2021-12-24 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения макулярного отека вследствие окклюзии ветви центральной вены сетчатки в сочетании с ретинальной артериолярной макроаневризмой
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
TW202525324A (zh) * 2023-08-17 2025-07-01 大陸商信達生物製藥（蘇州）有限公司 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法
CN118085112B (zh) * 2024-04-29 2024-08-09 上海鼎新基因科技有限公司 抗多个vegf家族蛋白的融合蛋白及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404297B1 (en) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2247289A4 (en) * 2008-02-21 2011-05-04 Ista Pharmaceuticals OPHTHALMIC NSAIDS AS ADJUVANTIES
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
MX337922B (es) * 2008-12-16 2016-03-28 Valeant Pharmaceuticals Int Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable.
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
EP3028707A1 (en) * 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"

Also Published As

Publication number Publication date
AU2017203923A1 (en) 2017-07-06
WO2015004616A1 (en) 2015-01-15
JP2016528202A (ja) 2016-09-15
EP3019526A1 (en) 2016-05-18
RU2676274C2 (ru) 2018-12-27
CA2917807A1 (en) 2015-01-15
AU2017203923B2 (en) 2018-10-18
US20180194835A1 (en) 2018-07-12
US20160168240A1 (en) 2016-06-16
AU2014288837A1 (en) 2015-12-10
CN105377891A (zh) 2016-03-02
RU2016104397A (ru) 2017-08-16
KR20160029794A (ko) 2016-03-15
BR112016000177A2 (pt) 2017-12-12
RU2016104397A3 (https=) 2018-05-31

Similar Documents

Publication Publication Date Title
MX2016000384A (es) Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.
MX2016000385A (es) Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad.
JP2012046524A5 (https=)
MX2017005875A (es) Metodos para tratar enfermedades oculares.
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
MY199027A (en) Method for treating or preventing ophthalmological conditions
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
WO2014080286A3 (en) Methods and compositions for treating multiple sclerosis and related disorders
HK1209341A1 (zh) 與治療柏金遜症相關之運動與動作障礙副作用之治療
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
FI3445351T3 (fi) Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen
MX374612B (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
PL3370693T3 (pl) Ulepszone preparaty lewosimendanu do podawania dożylnego w postaci roztworów do wlewów lub wstrzykiwań i koncentratu do wlewów
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
MX2020004106A (es) Metodo de tratamiento de trastornos neurodegenerativos.
GB201518170D0 (en) Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
AR102494A1 (es) Métodos para tratar enfermedades oculares
PH12014502497A1 (en) New treatments of hepatitis c virus infection